SAN FRANCISCO (
) --Welcome to the J.P. Morgan Biotech Confab Live Chat.
I'm here to offer my take on the first day of the biotech sector's largest and most important investor conference. And of course, I'm happy to answer your biotech stock investing questions.
This year's J.P. Morgan conference should be renamed the Hepatitis C Hoedown for the buzz being generated about
Bristol-Myers Squibb's
(BMY) - Get Report
$2.5 billion acquisition of
Inhibitex
( INHX) and the resulting speculative mania that is gripping
Idenix Pharmaceuticals
(IDIX)
and
Achillion Pharmaceuticals
(ACHN) - Get Report
. Both stocks are seen as potential takeover targets, too, but how likely is that or is it just wishful thinking?
I spent my day listening to presentations by
Celgene
(CELG) - Get Report
,
Onyx Pharmaceuticals
(ONXX)
,
Amarin
(AMRN) - Get Report
,
Vivus,
(VVUS) - Get Report
and
Dendreon
(DNDN)
.
--Written by Adam Feuerstein in San Francisco.
>To contact the writer of this article, click here:
.
>To follow the writer on Twitter, go to
http://twitter.com/adamfeuerstein
.
>To submit a news tip, send an email to:
.
Follow
TheStreet
on
and become a fan on
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
